Our Successes

For over 30 years, PharmaVentures has acted as advisor on over 1,000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
Here we show a few project examples to illustrate the PharmaVentures expertise.

PharmaVentures advises Douglas Pharmaceuticals on its licensing deal with Daré Bioscience

PharmaVentures advises Douglas Pharmaceuticals on its licensing deal with Daré Bioscience

PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)

PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)

PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics

PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

PharmaVentures acts as advisor to IntoCell on their ongoing collaboration agreement with Cellectar

PharmaVentures acts as advisor to IntoCell on their ongoing collaboration agreement with Cellectar

PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM

PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM

PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor

PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor

PharmaVentures advises Novartis on the sale of its manufacturing facility in Barberà del Vallès to Siegfried Holding AG

PharmaVentures advises Novartis on the sale of its manufacturing facility in Barberà del Vallès to Siegfried Holding AG

PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma

PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma

PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.

PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.

PharmaVentures Capital Limited advises Biosceptre International Limited, a clinical stage oncology company, on its Series A private placement by Tuspark S&T

PharmaVentures Capital Limited advises Biosceptre International Limited, a clinical stage oncology company, on its Series A private placement by Tuspark S&T

PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I’rom Group Co. Ltd.

PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I’rom Group Co. Ltd.

PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics

PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics

PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today

PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today

PharmaVentures advises Transgene on the sale of their biopharmaceutical manufacturing facility

PharmaVentures advises Transgene on the sale of their biopharmaceutical manufacturing facility

PharmaVentures advises Stericool on sale to Sweden’s Getinge Group

PharmaVentures advises Stericool on sale to Sweden’s Getinge Group

MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering

MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering

PharmaVentures’ Latest Deal: Douglas Pharmaceuticals acquires Vital Foods’ Phloe product line in New Zealand

PharmaVentures’ Latest Deal: Douglas Pharmaceuticals acquires Vital Foods’ Phloe product line in New Zealand

PharmaVentures Completes M&A Deal for Technology in the Stem Cell and Regenerative Medicine Sector

PharmaVentures Completes M&A Deal for Technology in the Stem Cell and Regenerative Medicine Sector

Another successful pharma divestment by PharmaVentures

Another successful pharma divestment by PharmaVentures

PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain

PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain

PharmaVentures acts as exclusive advisor on the sale of Medical Insight to Karos Health

PharmaVentures acts as exclusive advisor on the sale of Medical Insight to Karos Health

PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease

PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease

PharmaVentures Divests Manufacturing Facility for Major Pharma Client

PharmaVentures Divests Manufacturing Facility for Major Pharma Client

PharmaVentures advised Nanosight on its sale to Spectris plc.

PharmaVentures advised Nanosight on its sale to Spectris plc.

Valuation advisor to Yuhan Corporation on its licensing of Lazertinib for NSCLC to Janssen

Valuation advisor to Yuhan Corporation on its licensing of Lazertinib for NSCLC to Janssen

PharmaVentures advised Dogu Tip on its sale to Gulf Capital

PharmaVentures advised Dogu Tip on its sale to Gulf Capital

PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva’s Hlovovec Production Facility to Wood Pharma Holding

PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva’s Hlovovec Production Facility to Wood Pharma Holding

PharmaVentures helps secure investor for former MSD research site

PharmaVentures helps secure investor for former MSD research site

PharmaVenture Client Bergen Bio Licenses R428

PharmaVenture Client Bergen Bio Licenses R428

PharmaVentures Client QRx Pharma Announces Strategic Partnership with Actavis

PharmaVentures Client QRx Pharma Announces Strategic Partnership with Actavis

PharmaVentures facilitates manufacturing divestment for UCB to Aesica Pharmaceuticals

PharmaVentures facilitates manufacturing divestment for UCB to Aesica Pharmaceuticals

PharmaVentures acts as advisor and broker to Dr Reddy’s to identify and secure product marketing opportunities for the Russian/CIS market.

PharmaVentures acts as advisor and broker to Dr Reddy’s to identify and secure product marketing opportunities for the Russian/CIS market.

PharmaVentures acts as exclusive advisor to Sanofi-Aventis in landmark divestment deal with Covance

PharmaVentures acts as exclusive advisor to Sanofi-Aventis in landmark divestment deal with Covance